CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

apomorphine hydrochloride

Last Updated: September 9, 2020
Result type: Reports
Project Number: SR0650-000
Product Line: Common Drug Review

Generic Name: apomorphine hydrochloride

Brand Name: Kynmobi

Manufacturer: Sunovion Pharmaceuticals Canada Inc.

Indications: Parkinson’s disease

Manufacturer Requested Reimbursement Criteria1: Indicated for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMay 29, 2020
Call for patient input closedJuly 20, 2020
Clarification:

- Patient input submission received from The Michael J. Fox Foundation for Parkinson’s Research, Parkinson Association of Alberta, Parkinson Canada, Parkinson Quebec and Parkinson Society BC (PSBC)

Submission receivedJune 25, 2020
Clarification:

Submission was previously withdrawn and has been refiled by the sponsor

Submission acceptedJuly 10, 2020
Review initiatedJuly 13, 2020
Draft CADTH review report(s) provided to sponsor for commentAugust 28, 2020
Deadline for sponsors commentsSeptember 09, 2020
CADTH responses on draft review report(s) provided to sponsorOctober 08, 2020
Expert committee meeting (initial)October 21, 2020
Draft recommendation issuedNovember 02, 2020
To
November 04, 2020